STAT April 30, 2024
The U.S. Federal Trade Commission expanded its campaign against pharmaceutical companies for filing what it calls “junk” patent listings pertaining to 20 different brand-name treatments for asthma, COPD, diabetes, and weight loss, including the blockbuster Ozempic diabetes medicine sold by Novo Nordisk.
The move is part of an effort by the Biden administration to curb alleged patent abuses by the pharmaceutical industry. Drug companies have increasingly been accused of filing improper or inaccurate patents to make it harder for generic companies to sell...
Today's Sponsors
Today's Sponsor